Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Wisconsin, Madison
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospital, Basel, Switzerland
Vanderbilt-Ingram Cancer Center
City of Hope Medical Center
Vanderbilt-Ingram Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
University of Louisville
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
Rutgers, The State University of New Jersey
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Vanderbilt University
Indiana University
University of Minnesota
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Roswell Park Cancer Institute
Northwestern University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center